Centre of Experimental Medicine, Slovak Academy of Science
The Centre of Experimental Medicine (CEM) of the Slovak Academy of Sciences (SAS) was established on 1 January 2018 by merging of the Institute of Experimental Pharmacology and Toxicology (IEFT), the Institute of Normal and Pathological Physiology (INPP) and the Institute of Heart Research (IHR) into one Centre .
CEM focuses on the integrated research into the causes, mechanisms of development and possibilities of prevention, diagnosis and treatment of societally important diseases with the emphasis on diseases of the cardiovascular and the nervous systems, metabolic disorders, mental disorders and mental health problems as well as diseases originating in the prenatal and early postnatal developmental periods. The research in CEM is carried out on in silico, in vitro, ex vivo and in vivo models with the aim to transfer the acquired knowledge to clinical practice.
An important part is the evaluation of the effects of bioactive natural substances, their derivatives and original synthetic substances with pharmacotherapeutic potential, animal models of human diseases as well as the study of side-effects of toxic and chemical agents and radiation. A GLP unit of IEFT also provides to external parties contract research services related to in toxicology.
The CEM is a partner of the University science park for biomedicine - BioMedPark in Bratislava.
Link to the web: http://cem.sav.sk/
TraiN-SafeMDs team at CEM
Dr. Helena Kandarova, ERT
Responsible for the overall project management of the TraiN-Safe MDs project as well as activities conducted at CEM
Peter Pôbiš, MSc
Peter works predominantly with 3D models of human epithelial models, including oral and gingival tissues. His training will focus on the assessment of irritation, inflammation, and in later stages sensitization, and tissue engineering of the oral 3D epithelial models.
Júlia Kubalcová, Bc
Student at FCHPT
Julia works predominantly with 3T3 cell line and is focusing on the aspects of ISO 10993-5 and ISO 10993-12. Her training at CEM will focus on the assessment of cytotoxic potential of selected materials.
PharmDr. Michala Piešová (involved in the project in 2020)
Michaela is involved with the in vivo aspects of the testing of medical devices. She is working on the identification of the approaches that may lead to the reduction and
refinement of animal testing.